Evidence map›Paper›PMID 41495035›Full record

ArticleBlood cancer journal2026

Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia.

Sophie Steinhäuser, Thomas Beder, Emely Hübner, Dorothea S Feuereisel, Jonathan Jebens, Nadine Wolgast, Muhammed Bilal Karaca, Kathrin Richter, Nina Hedemann, Britta Steer and 12 more

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sophie Steinhäuser *Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0001-6985-0896
Thomas Beder *Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0009-0000-2278-5054
Emely Hübner *Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Dorothea S FeuereiselDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Jonathan JebensDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Nadine WolgastDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Muhammed Bilal KaracaDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Kathrin RichterDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Nina HedemannUniversity Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel and Lübeck, Germany.
Britta SteerDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Miriam DenkerDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Sonja BendigDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Monika BrüggemannDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0001-5514-5010
Patricia SilvaCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.
Lars FranseckyDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Martin NeumannDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Friedrich StölzelDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0003-0653-5332
Alina M HartmannDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.
Timo GemollUniversity Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel and Lübeck, Germany.
Lorenz BastianDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0002-1487-9437
Claudia D BaldusDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0002-0748-834X
Simone LipinskiDepartment of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany. Simone.S.Lipinski@gmail.com.ORCID http://orcid.org/0000-0002-9322-7372

Funding

José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) DJCLS 03 SP/2024José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) DJCLS 21R/2022
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41495035
PMCPMC12775398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.